The FDA on April 3, 2023, granted accelerated approval to PADCEV® with KEYTRUDA® for patients with locally advanced or metastatic Urothelial Carcinoma who are ineligible for Cisplatin-containing chemotherapy. PADCEV® is a product of Astellas Pharma and KEYTRUDA® is a product of Merck.
Other Pages – Bottom Ad
Advertisement
Subscribe
